SLC2A6

Across TCGA pan-cancer cohorts, SLC2A6 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of SLC2A6’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where SLC2A6 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types SLC2A6 is over-expressed in tumor, although a few such as LSCC and LUAD show the opposite, repressed pattern.

LSCC, LUAD, and PDAC are the cancer types where SLC2A6 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLC2A6 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Male	II,III,IV	−0.799	<.001	8	view →
LUAD	Male	II,III,IV	−0.740	<.001	8	view →
PDAC	All	All	+0.621	.001	4	view →
CCRCC	All	All	+0.334	.014	2	view →
HNSC	Male	All	+0.264	.038	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

SLC2A6–LSCC

Open the LSCC breakdown →